Literature DB >> 17135986

Acute time to response in the Treatment for Adolescents with Depression Study (TADS).

Christopher Kratochvil1, Graham Emslie, Susan Silva, Steve McNulty, John Walkup, John Curry, Mark Reinecke, Benedetto Vitiello, Paul Rohde, Nora Feeny, Charles Casat, Sanjeev Pathak, Elizabeth Weller, Diane May, Taryn Mayes, Michele Robins, John March.   

Abstract

OBJECTIVE: To examine the time to response for both pharmacotherapy and psychotherapy in the Treatment for Adolescents with Depression Study (TADS).
METHOD: Adolescents (N = 439, ages 12 to 17 years) with major depressive disorder were randomized to fluoxetine (FLX), cognitive-behavioral therapy (CBT), their combination (COMB), or pill placebo (PBO). Defining response as very much improved or much improved on the Clinical Global Impression-Improvement Scale (CGI-I), survival analyses using Cox proportional hazards models, and Kaplan-Meier curves were conducted to evaluate time to first response and time to stable response for subjects receiving pharmacotherapy (COMB, FLX, PBO) as well as for subjects receiving CBT (COMB, CBT). Direct comparisons between pharmacotherapy and CBT were not made because of differences in visit schedules.
RESULTS: Based on pharmacotherapist CGI-I scores, COMB and FLX showed faster onset of benefit than PBO on time to response and time to stable response (p < .001), and COMB was faster than FLX on time to stable response (p = .034). The probability of sustained early response was approximately threefold greater for COMB than PBO, twofold greater for FLX than PBO, and 1.5-fold greater for COMB than FLX. On the psychotherapist CGI-I scores, both first response and stable response occurred faster in COMB than CBT (p < .001), with a probability of sustained early response approximately threefold greater for COMB than CBT.
CONCLUSIONS: In the acute treatment of depressed adolescents, FLX and COMB accelerate response relative to PBO, and COMB accelerates response relative to CBT alone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17135986     DOI: 10.1097/01.chi.0000237710.73755.14

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  13 in total

1.  Developing Cognitive Behavioral Therapy to Prevent Depressive Relapse in Youth.

Authors:  Beth D Kennard; Sunita M Stewart; Jennifer L Hughes; Robin B Jarrett; Graham J Emslie
Journal:  Cogn Behav Pract       Date:  2008-11-01

2.  Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder.

Authors:  Rongrong Tao; Graham J Emslie; Taryn L Mayes; Paul A Nakonezny; Betsy D Kennard
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-10       Impact factor: 2.576

Review 3.  Primary Pediatric Care Psychopharmacology: Focus on Medications for ADHD, Depression, and Anxiety.

Authors:  Jeffrey R Strawn; Eric T Dobson; Lisa L Giles
Journal:  Curr Probl Pediatr Adolesc Health Care       Date:  2016-12-30

4.  Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients.

Authors:  Cynthia A Prows; Todd G Nick; Shannon N Saldaña; Sanjeev Pathak; Chunyan Liu; Kejian Zhang; Zachary S Daniels; Alexander A Vinks; Tracy A Glauser
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-08       Impact factor: 2.576

5.  Promoting social skill development in children with pervasive developmental disorders: a feasibility and efficacy study.

Authors:  Kathleen Koenig; Susan Williams White; Maryellen Pachler; Monika Lau; Moira Lewis; Ami Klin; Lawrence Scahill
Journal:  J Autism Dev Disord       Date:  2010-10

Review 6.  From TADS and SOFTADS to TORDIA and beyond: what's new in the treatment of adolescent depression?

Authors:  Zheya Jenny Yu; Christopher J Kratochvil; Ronald A Weller; Mira Mooreville; Elizabeth B Weller
Journal:  Curr Psychiatry Rep       Date:  2010-04       Impact factor: 5.285

7.  Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone.

Authors:  Rachel Manber; Helena C Kraemer; Bruce A Arnow; Madhukar H Trivedi; A John Rush; Michael E Thase; Barbara O Rothbaum; Daniel N Klein; James H Kocsis; Alan J Gelenberg; Martin E Keller
Journal:  J Consult Clin Psychol       Date:  2008-06

8.  Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough?

Authors:  Elizabeth E Hathaway; John T Walkup; Jeffrey R Strawn
Journal:  Curr Probl Pediatr Adolesc Health Care       Date:  2018-01-12

Review 9.  Management of treatment-resistant depression in children and adolescents.

Authors:  Melissa DeFilippis; Karen Dineen Wagner
Journal:  Paediatr Drugs       Date:  2014-10       Impact factor: 3.022

10.  Detecting critical decision points in psychotherapy and psychotherapy + medication for chronic depression.

Authors:  Dana Steidtmann; Rachel Manber; Christine Blasey; John C Markowitz; Daniel N Klein; Barbara O Rothbaum; Michael E Thase; James H Kocsis; Bruce A Arnow
Journal:  J Consult Clin Psychol       Date:  2013-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.